Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Jul-Aug;13(4):228-32.
doi: 10.1310/hct1304-228.

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK

Edwin DeJesus  1 , Jürgen K Rockstroh, Jeffrey L Lennox, Michael S Saag, Adriano Lazzarin, Jing Zhao, Hong Wan, Anthony J Rodgers, Monica L Walker, Michael Miller, Mark J DiNubile, Bach-Yen Nguyen, Hedy Teppler, Randi Leavitt, Peter Sklar; STARTMRK Investigators
Collaborators, Affiliations
Clinical Trial

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK

Edwin DeJesus et al. HIV Clin Trials. 2012 Jul-Aug.

Erratum in

  • HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233

Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

Trial registration: ClinicalTrials.gov NCT00369941.

PubMed Disclaimer

Publication types

MeSH terms

Associated data